Dynavax

About Dynavax

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and Europe for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing its CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Dynavax GmbH is the European affiliate of Dynavax Technologies Corporation USA, located in Düsseldorf, Germany. For more than 25 years, we have been dedicated to the development and manufacturing of vaccines and biopharmaceuticals. Dynavax GmbH is led by an experienced management team with demonstrated expertise in vaccine and biopharmaceutical product development and manufacturing. Our success is seen through the production of recombinant proteins of our licensed technology platform. Produkte, Services, Leistungen As a center of excellence for commercial production we manufacture the drug substance for Heplisav B. The vaccine received approval by the US FDA in late 2017 and was approved in Europe in February 2021. Perspektiven für die Zukunft Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis, and universal influenza. Kennzahlen MitarbeiterCa. 110 Mitarbeiter am Standort Düsseldorf

Synonyms

Technologies (from Job Ads)

Hiring Locations

Headquarters

Loading map...

Company Info

Legal Form: GmbH

Company Size: 51 - 250

Job Ad Metrics

Job Ads found: 139

Job Ads per Month: 5.3

Hiring Locations: 2

Data Info